Annexon, Inc. (NASDAQ:ANNX) Shares Bought by Acadian Asset Management LLC

Acadian Asset Management LLC raised its holdings in Annexon, Inc. (NASDAQ:ANNX) by 9.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 957,993 shares of the company’s stock after buying an additional 83,969 shares during the period. Acadian Asset Management LLC’s holdings in Annexon were worth $6,867,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ANNX. SG Americas Securities LLC raised its stake in Annexon by 14.1% in the fourth quarter. SG Americas Securities LLC now owns 25,335 shares of the company’s stock valued at $115,000 after buying an additional 3,123 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Annexon by 53.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,924 shares of the company’s stock worth $54,000 after purchasing an additional 4,141 shares in the last quarter. Bain Capital Life Sciences Investors LLC increased its position in shares of Annexon by 41.4% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,061,719 shares of the company’s stock worth $36,600,000 after purchasing an additional 2,359,793 shares in the last quarter. Lighthouse Investment Partners LLC acquired a new stake in shares of Annexon during the fourth quarter worth about $306,000. Finally, BVF Inc. IL acquired a new stake in shares of Annexon during the fourth quarter worth about $31,780,000.

Annexon Trading Up 2.0 %

Shares of Annexon stock traded up $0.11 during trading on Monday, hitting $5.74. 800,614 shares of the company were exchanged, compared to its average volume of 2,159,226. Annexon, Inc. has a fifty-two week low of $1.57 and a fifty-two week high of $8.40. The firm has a 50 day moving average price of $5.16 and a 200 day moving average price of $5.21.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.11. Sell-side analysts anticipate that Annexon, Inc. will post -0.98 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on ANNX shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research report on Wednesday, June 5th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Annexon in a report on Tuesday, June 4th. JPMorgan Chase & Co. raised their price target on Annexon from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, April 1st. Needham & Company LLC reissued a “buy” rating and set a $16.00 price target on shares of Annexon in a report on Tuesday, June 4th. Finally, Wells Fargo & Company lowered their price target on Annexon from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, May 15th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $15.33.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.